Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 44.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,258,208 shares of the biopharmaceutical company’s stock after selling 1,015,751 shares during the period. Victory Capital Management Inc. owned about 0.42% of Amicus Therapeutics worth $13,438,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Assenagon Asset Management S.A. acquired a new stake in shares of Amicus Therapeutics during the second quarter worth about $8,386,000. M&G Plc increased its position in Amicus Therapeutics by 12.4% during the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after purchasing an additional 82,728 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Amicus Therapeutics by 7.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after buying an additional 7,304 shares during the period. Fiera Capital Corp boosted its stake in shares of Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after buying an additional 58,113 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its stake in shares of Amicus Therapeutics by 24.2% in the second quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock valued at $2,483,000 after buying an additional 48,802 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald upped their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target for the company. Finally, Guggenheim upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Price Performance

FOLD stock opened at $9.52 on Wednesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock’s 50 day moving average price is $10.92 and its 200 day moving average price is $10.60. The firm has a market cap of $2.84 billion, a P/E ratio of -28.00 and a beta of 0.68. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $11,083,175. This represents a 0.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 30,401 shares of company stock valued at $352,038 over the last quarter. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.